BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that the company will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, October 2, 2019 at 8:20 AM ET.
A live audio webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors. An archived replay will be available for 30 days following the presentation.
About resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. resTORbio’s lead program selectively inhibits TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including immune, neurologic and cardiac function. Learn more about resTORbio, Inc. at www.resTORbio.com.
Investor Contact
Lauren Stival
Stern Investor Relations, Inc.
212-362-1200
lauren.stival@sternir.com
Media Contact
Lauren Arnold
MacDougall
781-235-3060
larnold@macbiocom.com
